Abstract AIMS Synergistic combinations of doxorubicin and gemcitabine have been assessed for post-surgical treatment IDH1 wild-type glioblastoma (GBM). As a complementary drug carrier, hyperbranched micellar nanoparticles are being investigated to enable enhanced loading sustained release. METHOD 2D 3D spheroid in vitro models generated from patient-derived cells resected tumour core invasive m...

BACKGROUND Cordycepin requires the relatively toxic co-drug, deoxycoformycin, for full efficacy as an anticancer agent. We sought to improve cordycepin efficacy using other, less toxic co-drugs. MATERIALS AND METHODS We evaluated the ability of hydroxyurea (HU) to enhance the effects of cordycepin against MOLT-4 leukemia cells with the MTT cell viability assay. We determined the relationship ...

BACKGROUND Brain tumor-initiating cells (BTICs) are stem-like cells hypothesized to form a disease reservoir that mediates tumor recurrence in high-grade gliomas. Oncolytic virotherapy uses replication-competent viruses to target and kill malignant cells and has been evaluated in clinic for glioma therapy with limited results. Myxoma virus (MyxV) is a safe and highly effective oncolytic virus (...

Dimethyl fumarate and dimethyl maleate are potent inducers of cytosolic NAD(P)H:(quinone acceptor) oxidoreductase (here designated quinone reductase) activity in Hepa 1c1c7 murine hepatoma cells in culture, whereas fumaric and maleic acids are much less potent, in agreement with the much greater reactivity of the esters as Michael reaction acceptors (P. Talalay, M. J. De Long, and H. J. Prochas...

Dimethyl fumarate and dimethyl maléate are potent inducers of cytosolic NAD(P)H:(quinone acceptor) oxidoreductase (here designated uninone reducÃ-ase)activity in Hepa Iclc? murine hepatoma cells in culture, whereas fumarie and maleic acids are much less potent, in agreement with the much greater reactivity of the esters as Michael reaction acceptors (P. Talalay, M. J. De Long, and H. J. Procha...

The idea of synergistic interactions between drugs and chemicals has been an important issue in the biomedical world for over a century. As complex diseases, especially cancer, are being treated with various drug cocktails, understanding the interactions among these drugs is increasingly vital to ensuring successful treatment regimens. However, the idea of synergy is not limited to only the bio...

Burton, R. B., Zaffaroni, A. & Keutman, E. H. (1951). J. biol. Chem. 188, 763. Callow, R. K (1950). Hormone A8eay, p. 384, ed. by C. W. Emmens. New York: Academic Press. Corcoran, A. C., Dustan, H. P. & Page, I. H. (1951) J. clin. Invest. 30, 633. Corcoran, A. C., Page, I. H. & Dustan, H. P. (1950). J. Lab. clin. Med. 37, 297. Cox, R. I. & Marrian, G. F. (1951). Biochem. J. 48, xxxiii. Daughada...

Dimethyl fumarate and dimethyl maléate are potent inducers of cytosolic NAD(P)H:(quinone acceptor) oxidoreductase (here designated uninone reducÃ-ase)activity in Hepa Iclc? murine hepatoma cells in culture, whereas fumarie and maleic acids are much less potent, in agreement with the much greater reactivity of the esters as Michael reaction acceptors (P. Talalay, M. J. De Long, and H. J. Procha...

Cutaneous T-cell lymphoma (CTCL) is a non-Hodgkin that presents with skin manifestations and often incurable at advanced stages blood involvement. Genomic profiling of malignant cells from CTCL patients has revealed diverse range genetic mutations underlying the disease, including single nucleotide gene copy number alterations involving JAK/STAT NF-κB signaling pathways. Synergistic drug combin...

For patients with sarcoma, metastatic disease remains very difficult to cure, and outcomes remain less than optimal. Treatment options have not largely changed, although some promising gains have been made with single agents in specific subtypes with the use of targeted agents. Here, we developed a system to investigate synergy of combinations of targeted and cytotoxic agents in a panel of sarc...